Hanall Biopharma Co., Ltd. (KRX:009420)

Market Cap	2.94T +119.1%
Revenue (ttm)	159.06B +12.8%
Net Income	-5.08B
EPS	-98.46
Shares Out	50.78M
PE Ratio	n/a
Forward PE	3,161.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	281,442
Open	52,800
Previous Close	57,900
Day's Range	50,500 - 54,200
52-Week Range	24,000 - 73,000
Beta	0.79
Analysts	Strong Buy
Price Target	90,000.00 (+77.87%)
Earnings Date	Aug 14, 2026

About Hanall Biopharma

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascul...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 304
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 009420

Financial Performance

In 2025, Hanall Biopharma's revenue was 155.18 billion, an increase of 11.69% compared to the previous year's 138.94 billion. Losses were -5.56 billion, 208.0% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for 009420 stock is "Strong Buy." The 12-month stock price target is ₩90,000, which is an increase of 77.87% from the latest price.

Price Target

₩90,000

(77.87% upside)

Analyst Consensus: Strong Buy